Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
21st Jan 20113:00 pmRNSBlocklisting Interim Review
2nd Dec 20104:00 pmRNSBlocklisting Interim Review
2nd Dec 20107:05 amRNSBoard Appointment
2nd Dec 20107:00 amRNSInterim results for the 6 months ended 31 October
1st Dec 20103:00 pmRNSTotal Voting Rights
2nd Nov 20109:19 amRNSTotal Voting Rights
22nd Oct 20101:37 pmRNSHolding(s) in Company
22nd Oct 20101:37 pmRNSHolding(s) in Company
18th Oct 20107:00 amRNSKing Systems - New Digital Technology
14th Oct 20107:00 amRNSBlock Listing Application
21st Sep 20104:10 pmRNSDirector/PDMR Shareholding
20th Sep 201012:21 pmRNSHolding(s) in Company
20th Sep 201012:01 pmRNSBlocklisting Interim Review
15th Sep 20103:16 pmRNSResult of AGM
15th Sep 201011:40 amRNSInterim Management Statement
12th Aug 20102:48 pmRNSAnnual Financial Report & Notice of AGM
9th Aug 201011:58 amRNSDirector/PDMR Shareholding
5th Aug 201010:17 amRNSNotifications of Major Interests in Shares
3rd Aug 20102:38 pmRNSNotification of Transactions of Directors
30th Jul 201010:20 amRNSDirector/PDMR Shareholding
22nd Jul 20102:32 pmRNSHolding(s) in Company
21st Jul 20102:40 pmRNSBlocklisting Interim Review
12th Jul 20103:24 pmRNSHolding(s) in Company
24th Jun 20102:49 pmRNSHolding(s) in Company
18th Jun 20104:40 pmRNSSecond Price Monitoring Extn
18th Jun 20104:35 pmRNSPrice Monitoring Extension
17th Jun 20102:54 pmRNSBlocklisting Interim Review
17th Jun 20107:00 amRNSPreliminary Results
14th Jun 20109:41 amRNSBlocklisting Interim Review
3rd Jun 201011:02 amRNSNotice of date of Full Year Preliminary Results
24th May 20104:41 pmRNSSecond Price Monitoring Extn
24th May 20104:36 pmRNSPrice Monitoring Extension
21st May 20109:32 amRNSChange of Adviser
16th Apr 201012:53 pmRNSHolding(s) in Company
8th Apr 201012:58 pmRNSHolding(s) in Company
6th Apr 20103:57 pmRNSDirector/PDMR Shareholding
1st Apr 20102:08 pmRNSRule 8.3- (Consort Medical Plc)
31st Mar 20109:03 amRNSDirector/PDMR Shareholding
25th Mar 201010:19 amRNSRule 8.3- Consort Medical Plc
19th Mar 20103:11 pmRNSRule 8.3- Consort Medical plc
19th Mar 20102:38 pmRNSRule 8.3- Consort Medical PLC
19th Mar 20102:14 pmRNSBlocklisting Interim Review
19th Mar 20107:00 amRNSInterim Management Statement
18th Mar 20104:50 pmRNSOffer Talks Terminated
18th Mar 20101:54 pmRNSRule 8.3- Consort Medical PLC
17th Mar 20102:13 pmRNSRule 8.3- Consort Medical PLC
16th Mar 201011:49 amRNSRule 8.3- Consort Medical PLC
15th Mar 20102:57 pmRNSRule 8.3- Consort Medical PLC
12th Mar 20102:22 pmRNSRule 8.3- Consort Medical PLC
12th Mar 201010:12 amRNSRule 8.3- (Consort Medical Plc)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.